M&A · Industry Consolidation · June 5, 2026

🔴 Breaking 💰 M&A

Med-Metrix Acquires Vitalware from Health Catalyst — What It Means for Mid-Revenue Cycle

Health Catalyst is selling Vitalware — the 5x Best in KLAS chargemaster platform it bought for $70M in 2020 — to PE-backed services operator Med-Metrix for $147 million in cash. The proceeds go straight to retiring Health Catalyst's $160M term loan. This isn't just a vendor shuffle. It's a debt-driven exit that hands a profitable mid-revenue cycle software business to an operator built to run it.

The Deal

Med-Metrix, LLC — backed by Harvest Partners and A&M Capital Partners — announced June 4, 2026 it has entered into a definitive agreement to acquire Vitalware from Health Catalyst (NASDAQ: HCAT) for $147 million in cash. Health Catalyst has filed an 8-K with the SEC. Raymond James acted as exclusive financial advisor to Health Catalyst; Latham & Watkins LLP provided legal counsel. The transaction is expected to close in 2026, subject to customary closing conditions. Vitalware's leadership team and employees are expected to be integrated into Med-Metrix post-close.

Free Daily RCM Intelligence

Denial trends, payer policy moves, vendor intel — delivered every morning. Free.

📧 Every Tuesday: The 3-Minute RCM Briefing

Payer shifts, denial patterns, and deal signals that hit your AR before you hear about them — 3 minutes, every Tuesday.

Join RCM professionals. Free. Unsubscribe anytime.

Read by leaders from:

Deal Snapshot

Acquirer: Med-Metrix, LLC (backed by Harvest Partners + A&M Capital Partners)
Target: Vitalware — cloud-based chargemaster management, revenue integrity, price transparency, coding analytics
Seller: Health Catalyst (NASDAQ: HCAT)
Deal price: $147M cash
Vitalware FY2025 revenue: ~$37M
Announced: June 4, 2026 · Expected close: 2026
Vitalware pedigree: Founded 2011, acquired by Health Catalyst 2020, 5x Best in KLAS chargemaster management
Advisors: Raymond James (Health Catalyst financial), Latham & Watkins LLP (Health Catalyst legal)

Why Health Catalyst Is Letting It Go

Health Catalyst paid roughly $70 million for Vitalware in 2020 with a thesis that combining a data analytics platform with mid-revenue cycle workflow software would create an integrated offering hospitals couldn't get elsewhere. Six years later, they're selling it for $147M — roughly doubling their money on paper — but the real story is what they're doing with the proceeds.

The entire $147M, combined with existing cash, goes directly toward repaying and terminating Health Catalyst's $160 million senior secured term loan (outstanding principal as of March 31, 2026). This isn't a strategic pivot dressed up as focus — it's a deleveraging transaction. Health Catalyst exits with a clean balance sheet and can finally fund its clinical AI roadmap without a nine-figure debt load hanging over it.

The business case is straightforward: Vitalware generated ~$37M in revenue in FY2025. At a $147M exit, that's roughly a 4x revenue multiple — solid for a software business in this environment. Health Catalyst takes the gain, kills the debt, and refocuses on what it was actually built to do: 18 years of healthcare data infrastructure, $2.8 billion in documented outcomes, and a clinical AI platform it couldn't fully invest in while carrying that loan.

CEO Ben Albert framed it diplomatically: "This strategic move opens our next phase, and we have found a tremendous partner in Med-Metrix to take Vitalware forward." The subtext: Vitalware needed an operator who would invest in it as a core product, not carry it as a non-core asset.

What Med-Metrix Gets

Med-Metrix already operates as an end-to-end RCM and business intelligence services platform for health systems and physician groups. What they've been missing is proprietary mid-revenue cycle software — the kind that sits in the workflow daily, owns the chargemaster, and drives coding accuracy before the claim ever drops.

Vitalware fills that gap directly:

Chargemaster management: 5x Best in KLAS. Widely adopted across hospitals and health systems for CDM governance, charge capture accuracy, and regulatory compliance.
Coding workflow tools: Bridges clinical documentation and the claim — the exact point where revenue leakage typically starts.
Price transparency: A compliance requirement that most health systems are still struggling to operationalize cleanly. Vitalware has tooling here.
Revenue integrity analytics: Flags where charge capture is breaking down before it hits accounts receivable.

Med-Metrix Co-President Rob Wright put it plainly: "By integrating their impressive software capabilities, we are better positioned to help providers improve reimbursement accuracy, manage compliance risk, and capture the full value of care delivered."

The strategic play

Med-Metrix is building the stack that most RCM outsourcers only half-have: operator-led services layered on top of proprietary workflow software. That combination is harder to displace than pure-play services or standalone software. The Vitalware acquisition accelerates that moat considerably.

What This Means If You're a Vitalware Client

If Vitalware's chargemaster or revenue integrity tools are in your stack, here's what to watch:

Short term, nothing changes operationally. The deal is still pending close and the Vitalware team is expected to integrate — not be restructured out. Your account reps and support contacts should remain intact initially.
Med-Metrix is an operator, not a software company. Expect them to push tighter integration between the software and services offerings. If you're currently a pure software client with no Med-Metrix services relationship, expect a commercial conversation about the broader platform.
Product investment direction may shift. Health Catalyst was a public data company. Med-Metrix is a PE-backed services operator. Investment priorities may tilt toward features that support services delivery rather than standalone analytics depth. Worth watching over 12–18 months.
Pricing structure is an open question. Post-close integration often brings pricing model reviews, particularly when the acquirer is building toward a bundled services + software offer.

The Bigger Picture: Mid-Revenue Cycle Is the Next Battleground

This deal is the latest in a string of moves signaling that the mid-revenue cycle — charge capture, CDM, coding accuracy, revenue integrity — is where PE and strategic capital is concentrating right now.

The back end of revenue cycle (AR follow-up, denial management, collections) has been outsourced for decades. The front end (prior auth, eligibility) is being disrupted by AI. That leaves the middle — the charge-to-claim workflow — as the highest-value, least-automated layer in the stack. Whoever owns that workflow with software, not just services, has leverage.

Med-Metrix just bought that leverage.

For health system RCM leaders: know who owns your CDM platform and what their roadmap looks like. Ownership changes have a way of accelerating or derailing product timelines in ways that directly affect your net revenue yield.

Track Payer Policy Changes That Affect Your Revenue Integrity

Published by RevCycleAI Research · June 5, 2026 · Source: Med-Metrix Press Release

RCM Job Board

RCMJobs.com

Revenue cycle jobs only — 300+ roles updated daily.

Browse Open Roles → Hiring? Post a Job — from $199

Daily RCM Intelligence

Stay ahead of what's moving revenue cycle.

Breaking deals, payer policy shifts, and RCM AI — before your competitors see it.

Read RevCycleAI →